Installer Kaleta App
Accès rapide & mode hors-ligne
Advancing antimalarial drug research and development
Medicines for Malaria Venture (MMV) is a leading product development partnership in the field of antimalarial drug research. Founded in 1999 and headquartered in Geneva, Switzerland, MMV was established with the mission to reduce the burden of malaria in disease-endemic countries by discovering, developing, and facilitating the delivery of new, effective, and affordable antimalarial drugs. The organization collaborates with a global network of pharmaceutical companies, research institutions, and governments to address the unmet medical needs of vulnerable populations, particularly in Africa.
MMV has significantly impacted the global fight against malaria by developing and launching several new antimalarial drugs that have saved millions of lives. The organization focuses on creating innovative therapies that address drug resistance and improve treatment outcomes. MMV’s work has expanded access to life-saving medications, particularly for children and pregnant women, and has contributed to the broader goal of malaria eradication. Through strategic partnerships and funding, MMV continues to drive research and development efforts that enhance global health and economic productivity.
MMV operates primarily in malaria-endemic regions, with a strong focus on African countries where the disease burden is highest. The organization collaborates with local governments, health ministries, and research institutions to ensure the effective distribution and use of antimalarial drugs. Key regional hubs include countries in sub-Saharan Africa, Southeast Asia, and parts of South America, where MMV’s interventions are most needed.
MMV’s flagship initiatives include the development of next-generation antimalarial therapies and the implementation of access programs that ensure the availability of these drugs in low-resource settings. The organization provides funding and technical support to research projects that focus on innovative drug discovery and development. MMV also partners with global health organizations to mobilize resources and foster collaborations that advance its mission.
MMV has achieved significant milestones, including the development of over 13 new antimalarial drugs that have been approved and are in use worldwide. These drugs have contributed to reducing malaria mortality rates, particularly among children under five. MMV’s efforts have been recognized through numerous awards and accolades, highlighting its role in transforming malaria treatment and prevention strategies globally.
